Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia: Similar Outcomes Regardless of Donor Type

Erica D. Warlick; Regis Peffault de Latour; Ryan Shanley; Marie Robin; Nelli Bejanyan; Alienor Xhaard; Claudio Brunstein; Flore Sicre de Fontbrune; Celalettin Ustun; Daniel J. Weisdorf; Gerard Socie

doi:10.1016/j.bbmt.2014.10.030

Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia: Similar Outcomes Regardless of Donor Type

Erica D. Warlick, Regis Peffault de Latour, Ryan Shanley, Marie Robin, Nelli Bejanyan, Alienor Xhaard, Claudio Brunstein, Flore Sicre de Fontbrune, Celalettin Ustun, Daniel J. Weisdorf, Gerard Socie

Research output: Contribution to journal › Article › peer-review

34 Scopus citations

Abstract

The use of alternative donor transplants is increasing as the transplantation-eligible population ages and sibling donors are less available. We evaluated the impact of donor source on transplantation outcomes for adults with acute myeloid leukemia undergoing myeloablative (MA) or reduced-intensity conditioning (RIC) transplantation. Between January 2000 and December 2010, 414 consecutive adult patients with acute myeloid leukemia in remission received MA or RIC allogeneic transplantation from either a matched related donor (n=187), unrelated donor (n=76), or umbilical cord blood donor (n=151) at the University of Minnesota or HÔpital St. Louis in Paris. We noted similar 6-year overall survival across donor types: matched related donor, 47% (95% confidence interval [CI], 39% to 54%); umbilical cord blood, 36% (95% CI, 28% to 44%); matched unrelated donor, 54% (95% CI, 40% to 66%); and mismatched unrelated donor, 51% (95% CI, 28% to 70%) (. P <.11). Survival differed based on conditioning intensity and age, with 6-year survival of 57% (95% CI, 47% to 65%), 39% (95% CI, 28% to 49%), 23% (95% CI, 6% to 47%), 47% (95% CI, 36% to 57%), and 28% (95% CI, 17% to 41%) for MA age 18 to 39, MA age 40+, or RIC ages 18 to 39, 40 to 56, and 57 to 74, respectively (. P<.01). Relapse was increased with RIC and lowest in younger patients receiving MA conditioning (hazard ratio, 1.0 versus 2.5 or above for all RIC age cohorts), P <.01. Transplantation-related mortality was similar across donor types. In summary, our data support the use of alternative donors as a graft source with MA or RIC for patients with acute myeloid leukemia when a sibling donor is unavailable.

Original language	English (US)
Pages (from-to)	357-363
Number of pages	7
Journal	Biology of Blood and Marrow Transplantation
Volume	21
Issue number	2
DOIs	https://doi.org/10.1016/j.bbmt.2014.10.030
State	Published - Feb 1 2015

Bibliographical note

Funding Information:
Financial disclosure: This work was supported in part by grants from the National Cancer Institute P01 CA65493 (C.G.B) and Leukemia and Lymphoma Society Scholar in Clinical Research Award, grant R6029-07 (C.G.B.). This work was also supported in part by National Institutes of Health grant P30 CA77598 utilizing Biostatistics and Bioinformatics Core shared resource of the Masonic Cancer Center, University of Minnesota and by the National Center for Advancing Translational Sciences of the National Institutes of Health Award Number UL1TR000114. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Publisher Copyright:
© 2015 American Society for Blood and Marrow Transplantation.

Keywords

Acute myeloid leukemia
Allogeneic hematopoietic stem cell transplantation

Publisher link

10.1016/j.bbmt.2014.10.030

Find It

Find It at U of M Libraries

Cite this

Warlick, E. D., Peffault de Latour, R., Shanley, R., Robin, M., Bejanyan, N., Xhaard, A., Brunstein, C., Sicre de Fontbrune, F., Ustun, C., Weisdorf, D. J., & Socie, G. (2015). Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia: Similar Outcomes Regardless of Donor Type. Biology of Blood and Marrow Transplantation, 21(2), 357-363. https://doi.org/10.1016/j.bbmt.2014.10.030

Warlick, ED, Peffault de Latour, R, Shanley, R, Robin, M, Bejanyan, N, Xhaard, A, Brunstein, C, Sicre de Fontbrune, F, Ustun, C, Weisdorf, DJ & Socie, G 2015, 'Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia: Similar Outcomes Regardless of Donor Type', Biology of Blood and Marrow Transplantation, vol. 21, no. 2, pp. 357-363. https://doi.org/10.1016/j.bbmt.2014.10.030

@article{19665c73aa364cf2a751e3a89770a7f2,

title = "Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia: Similar Outcomes Regardless of Donor Type",

abstract = "The use of alternative donor transplants is increasing as the transplantation-eligible population ages and sibling donors are less available. We evaluated the impact of donor source on transplantation outcomes for adults with acute myeloid leukemia undergoing myeloablative (MA) or reduced-intensity conditioning (RIC) transplantation. Between January 2000 and December 2010, 414 consecutive adult patients with acute myeloid leukemia in remission received MA or RIC allogeneic transplantation from either a matched related donor (n=187), unrelated donor (n=76), or umbilical cord blood donor (n=151) at the University of Minnesota or H{\^O}pital St. Louis in Paris. We noted similar 6-year overall survival across donor types: matched related donor, 47% (95% confidence interval [CI], 39% to 54%); umbilical cord blood, 36% (95% CI, 28% to 44%); matched unrelated donor, 54% (95% CI, 40% to 66%); and mismatched unrelated donor, 51% (95% CI, 28% to 70%) (. P <.11). Survival differed based on conditioning intensity and age, with 6-year survival of 57% (95% CI, 47% to 65%), 39% (95% CI, 28% to 49%), 23% (95% CI, 6% to 47%), 47% (95% CI, 36% to 57%), and 28% (95% CI, 17% to 41%) for MA age 18 to 39, MA age 40+, or RIC ages 18 to 39, 40 to 56, and 57 to 74, respectively (. P<.01). Relapse was increased with RIC and lowest in younger patients receiving MA conditioning (hazard ratio, 1.0 versus 2.5 or above for all RIC age cohorts), P <.01. Transplantation-related mortality was similar across donor types. In summary, our data support the use of alternative donors as a graft source with MA or RIC for patients with acute myeloid leukemia when a sibling donor is unavailable.",

keywords = "Acute myeloid leukemia, Allogeneic hematopoietic stem cell transplantation",

author = "Warlick, {Erica D.} and {Peffault de Latour}, Regis and Ryan Shanley and Marie Robin and Nelli Bejanyan and Alienor Xhaard and Claudio Brunstein and {Sicre de Fontbrune}, Flore and Celalettin Ustun and Weisdorf, {Daniel J.} and Gerard Socie",

note = "Funding Information: Financial disclosure: This work was supported in part by grants from the National Cancer Institute P01 CA65493 (C.G.B) and Leukemia and Lymphoma Society Scholar in Clinical Research Award, grant R6029-07 (C.G.B.). This work was also supported in part by National Institutes of Health grant P30 CA77598 utilizing Biostatistics and Bioinformatics Core shared resource of the Masonic Cancer Center, University of Minnesota and by the National Center for Advancing Translational Sciences of the National Institutes of Health Award Number UL1TR000114. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Publisher Copyright: {\textcopyright} 2015 American Society for Blood and Marrow Transplantation.",

year = "2015",

month = feb,

day = "1",

doi = "10.1016/j.bbmt.2014.10.030",

language = "English (US)",

volume = "21",

pages = "357--363",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1083-8791",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia

T2 - Similar Outcomes Regardless of Donor Type

AU - Warlick, Erica D.

AU - Peffault de Latour, Regis

AU - Shanley, Ryan

AU - Robin, Marie

AU - Bejanyan, Nelli

AU - Xhaard, Alienor

AU - Brunstein, Claudio

AU - Sicre de Fontbrune, Flore

AU - Ustun, Celalettin

AU - Weisdorf, Daniel J.

AU - Socie, Gerard

N1 - Funding Information: Financial disclosure: This work was supported in part by grants from the National Cancer Institute P01 CA65493 (C.G.B) and Leukemia and Lymphoma Society Scholar in Clinical Research Award, grant R6029-07 (C.G.B.). This work was also supported in part by National Institutes of Health grant P30 CA77598 utilizing Biostatistics and Bioinformatics Core shared resource of the Masonic Cancer Center, University of Minnesota and by the National Center for Advancing Translational Sciences of the National Institutes of Health Award Number UL1TR000114. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Publisher Copyright: © 2015 American Society for Blood and Marrow Transplantation.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - The use of alternative donor transplants is increasing as the transplantation-eligible population ages and sibling donors are less available. We evaluated the impact of donor source on transplantation outcomes for adults with acute myeloid leukemia undergoing myeloablative (MA) or reduced-intensity conditioning (RIC) transplantation. Between January 2000 and December 2010, 414 consecutive adult patients with acute myeloid leukemia in remission received MA or RIC allogeneic transplantation from either a matched related donor (n=187), unrelated donor (n=76), or umbilical cord blood donor (n=151) at the University of Minnesota or HÔpital St. Louis in Paris. We noted similar 6-year overall survival across donor types: matched related donor, 47% (95% confidence interval [CI], 39% to 54%); umbilical cord blood, 36% (95% CI, 28% to 44%); matched unrelated donor, 54% (95% CI, 40% to 66%); and mismatched unrelated donor, 51% (95% CI, 28% to 70%) (. P <.11). Survival differed based on conditioning intensity and age, with 6-year survival of 57% (95% CI, 47% to 65%), 39% (95% CI, 28% to 49%), 23% (95% CI, 6% to 47%), 47% (95% CI, 36% to 57%), and 28% (95% CI, 17% to 41%) for MA age 18 to 39, MA age 40+, or RIC ages 18 to 39, 40 to 56, and 57 to 74, respectively (. P<.01). Relapse was increased with RIC and lowest in younger patients receiving MA conditioning (hazard ratio, 1.0 versus 2.5 or above for all RIC age cohorts), P <.01. Transplantation-related mortality was similar across donor types. In summary, our data support the use of alternative donors as a graft source with MA or RIC for patients with acute myeloid leukemia when a sibling donor is unavailable.

AB - The use of alternative donor transplants is increasing as the transplantation-eligible population ages and sibling donors are less available. We evaluated the impact of donor source on transplantation outcomes for adults with acute myeloid leukemia undergoing myeloablative (MA) or reduced-intensity conditioning (RIC) transplantation. Between January 2000 and December 2010, 414 consecutive adult patients with acute myeloid leukemia in remission received MA or RIC allogeneic transplantation from either a matched related donor (n=187), unrelated donor (n=76), or umbilical cord blood donor (n=151) at the University of Minnesota or HÔpital St. Louis in Paris. We noted similar 6-year overall survival across donor types: matched related donor, 47% (95% confidence interval [CI], 39% to 54%); umbilical cord blood, 36% (95% CI, 28% to 44%); matched unrelated donor, 54% (95% CI, 40% to 66%); and mismatched unrelated donor, 51% (95% CI, 28% to 70%) (. P <.11). Survival differed based on conditioning intensity and age, with 6-year survival of 57% (95% CI, 47% to 65%), 39% (95% CI, 28% to 49%), 23% (95% CI, 6% to 47%), 47% (95% CI, 36% to 57%), and 28% (95% CI, 17% to 41%) for MA age 18 to 39, MA age 40+, or RIC ages 18 to 39, 40 to 56, and 57 to 74, respectively (. P<.01). Relapse was increased with RIC and lowest in younger patients receiving MA conditioning (hazard ratio, 1.0 versus 2.5 or above for all RIC age cohorts), P <.01. Transplantation-related mortality was similar across donor types. In summary, our data support the use of alternative donors as a graft source with MA or RIC for patients with acute myeloid leukemia when a sibling donor is unavailable.

KW - Acute myeloid leukemia

KW - Allogeneic hematopoietic stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=84920895524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920895524&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2014.10.030

DO - 10.1016/j.bbmt.2014.10.030

M3 - Article

C2 - 25452032

AN - SCOPUS:84920895524

VL - 21

SP - 357

EP - 363

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 2

ER -

Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia: Similar Outcomes Regardless of Donor Type

Abstract

Bibliographical note

Keywords

Publisher link

Find It

Other files and links

Fingerprint

Cite this